Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.71 |
| ▸ | DHFR | P00374 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | CASP1 | P29466 | 4/20 | 0.65 |
| ▸ | CASP7 | P55210 | 4/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.65 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.65 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.65 |
| ▸ | RECQL | P46063 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735945 | 0.90 | MEN1 (0.71) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL5425962 | 0.89 | MEN1 (0.66) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL6834225 | 0.87 | MEN1 (0.68) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL14696988 | 0.84 | KDM4E (0.58) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL505415 | 0.84 | DHFR (0.68) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL2281134 | 0.83 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL505584 | 0.81 | MEN1 (0.79) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL1627936 | 0.81 | CYP3A4 (0.82) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL15456750 | 0.81 | CYP3A4 (0.82) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL1628821 | 0.80 | DHFR (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20160367497-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY | 2016-12-22 | — | — | US | claimed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | claimed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-20100047177-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2010-02-25 | — | — | US | claimed |
| EP-2124985-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008091710-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2008-07-31 | — | — | WO | claimed |
| US-20060002914-A1 | treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent (such as NAD, NADH) that increases sirtuin activity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250114380-A1 | SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005065667-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1391327-A1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114380-A1 | SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME | CD38, BCL6B, DNASE1L3 | MEN1 3469/4885KMT2A 1199/4885CYP3A4 4721/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MEN1 1105/4885KMT2A 4260/4885CYP3A4 4828/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | MEN1 3867/4885KMT2A 4306/4885CYP3A4 3010/4885 |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | FABP4, GPR119, SIRT1 | MEN1 4290/4885KMT2A 1345/4885CYP3A4 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.